| Garcia2009 - Long-term Clinical Symptoms Post-Dengue | 2009 | Int J Infect Dis | 133 / 110 | Post-dengue syndrome, FcγRIIa polymorphism, autoimmunity, Cuba DENV-4 |
| Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism | 2010 | Am J Trop Med Hyg | 23 / 83 | FcγRIIa-RR protective against symptomatic dengue; asymptomatic infection; Cuba population genetics |
| Tan1997 - ANA Range in Healthy Individuals | 1997 | Arthritis & Rheumatism | 381 / 267 | ANA normal range; healthy-population reference; 15-lab multicentre; 1:40–1:320 |
| Satoh2012 - ANA Prevalence in United States | 2012 | Arthritis & Rheumatism | 424 / 386 | ANA prevalence US population; NHANES; sociodemographic correlates; 13.8% at 1:80 |
| Li2019 - ANA Epidemiology in Chinese Healthy Population | 2019 | J Clin Lab Anal | 39 / 37 | ANA prevalence Chinese health-checkup population; AMA-M2; anti-SSA; 14.01% at >1:100 |
| Aringer2019 - 2019 EULAR ACR SLE Classification Criteria | 2019 | Arthritis & Rheumatology | 2248 / 1973 | 2019 EULAR/ACR SLE criteria; ANA ≥1:80 as mandatory entry criterion; sensitivity 96.1% |
| Dinse2022 - Increasing ANA Prevalence in United States | 2022 | Arthritis & Rheumatology | 53 / 68 | Rising ANA prevalence in US 1988–2012; 11.0%→16.1%; adolescent increase; NHANES |
| Berlin2007 - Autoantibodies in Nonautoimmune Individuals during Infections | 2007 | Ann NY Acad Sci | 78 / 60 | ANA 21.7% during acute viral infections vs. 3.8% controls; anti-annexin-V/prothrombin; multi-infection comparison |
| Johnson2022 - Infectious Diseases Autoantibodies and Autoimmunity | 2022 | J Autoimmun | 52 / 52 | Molecular mimicry, bystander activation, epitope spreading; review of infection-triggered autoimmunity mechanisms |
| Sungnak2025 - Distinct Immune Responses Asymptomatic Symptomatic Dengue | 2025 | Sci Transl Med | 1 / 1 | scRNA-seq + V(D)J sequencing; asymptomatic vs. DF vs. DHF; CD8 TEM effector vs. exhausted; NK FcεRIγ phenotype; ADE transcriptomics; IGHG1/IGHA1 plasmablasts; public BCR clonotype; IL-10; IFN-α; Thailand DENFREE cohort |
| Lin2006 - Autoimmune Pathogenesis in Dengue Virus Infection | 2006 | Viral Immunology | 182 / 110 | NS1 molecular mimicry; anti-platelet IgM autoAbs; endothelial apoptosis; NF-κB inflammation; DHF/DSS; NCKU Taiwan |
| Lin2011 - Molecular Mimicry Virus Host Dengue Pathogenesis | 2011 | Exp Biol Med | 128 / 107 | NS1 molecular targets (PDI/vimentin/HSP60/ATP-synthase β); C-terminal NS1 aa 311–352; WGNGCG coagulation motif; anti-prM/HSP60; flavivirus comparison; acute-phase autoimmunity |
| Guzman2016 - Dengue Infection | 2016 | Nat Rev Dis Primers | 687 / 634 | Comprehensive dengue review; global burden; virology; ADE conditional virulence; pathophysiology (NS1-TLR4, thrombin, APTT, thrombocytopenia, complement, liver); host genetics Table 2; vaccines (CYD-TDV, TAK-003, TV003, subunit, inactivated); vector biology; vector control (Cuba, Singapore, Wolbachia, SIT) |
| Bruhns2009 - FcγR Specificity and Affinity for IgG Subclasses | 2009 | Blood | 1444 / 1303 | SPR affinity of all 6 hFcγRs for IgG1–4; H131 4.5× higher IgG2 affinity than R131; FcγRIIB ~43× weaker than FcγRIIA for IgG1; FcγRIIIA-V158 monomeric IgG3 binding; fucosylation effect on FcγRIII |
| Li2018 - Increased Risk of Autoimmune Diseases in Dengue | 2018 | J Infect | 38 / 40 | ICD-coded NHIRD cohort (n=12,506); aHR 1.88 overall; primary adrenocortical insufficiency most frequent [aHR 2.05]; ADEM [aHR 3.80]; SLE [aHR 3.50]; GBS non-significant; TLR/adrenocortical mechanism; critiqued by Shih2023 |
| Shih2023 - Autoimmune Disease Risk After Dengue | 2023 | PLoS Negl Trop Dis | 17 / 18 | Population-based cohort (63,814 lab-confirmed dengue); Taiwan NHIRD; only ADEM elevated after dengue (aHR 2.72); refutes Li et al. 2018 broad autoimmune claim; 51.4% misclassification rate in prior studies; NS1 RDT rollout impact |
| Wan2012 - Autoimmunity in Dengue Pathogenesis | 2012 | J Formos Med Assoc | 92 / 77 | Capstone NCKU review; autoantibody kinetics (acute peak, months persistence); LYRIC/RGD/capsid mimicry; intrinsic ADE; NS1 vaccine paradox; Taiwan epidemiology |
| Chatterjee2024 - ANA Detection in Dengue Kolkata | 2024 | Virulence | 2 / 2 | ANA in acute dengue; HEp-2 IIFA 54.8% vs. 10.3% controls; LIA 18.5%; ~66% IIFA-positives non-specific; MCTD and myositis significantly elevated; Kolkata India hospital-based; n=135 |
| Seet2007 - Post-Infectious Fatigue Syndrome in Dengue | 2007 | J Clin Virology | 140 / 126 | Post-dengue fatigue; 24.4% at 2 months; severity-independence; OR 9.687 female sex; Singapore DEN-1 outbreak; n=127 |
| Bos2025 - Longitudinal Antibody Dynamics After Dengue | 2025 | medRxiv (PREPRINT) | 0 / 0 | XR E-IgG rising 6–18M post-primary (t½=−2.13y); NS1-IgG waning (t½≈2.1y); EDI/II vs EDIII domain specificity; IgA/IgM/IgG3/IgG4 kinetics at 18M; Nicaragua HIMJR pediatric cohort; n=79 |